

# Vascular Closure Device Type Impacts Bleeding and Vascular Complications After TAVR:

## *Results from the BRAVO 3 Randomized Trial*

David Power MD, Ulrich Schäfer MD, Paul Guedeney MD, Bimmer E Claessen MD PhD, Samantha Sartori PhD, Christian Kupatt MD, Didier Tchetché MD, Christian Hengstenberg MD, Roxana Mehran MD MSCAI, George Dangas MD MSCAI

*The BRAVO-3 Investigators*



**SCAI**

Society for Cardiovascular  
Angiography & Interventions

# Study Objectives

- To investigate **the impact of type of vascular closure device on clinical outcomes after transfemoral TAVR** in the large randomized BRAVO-3 trial population


- Major Bleeding (BARC criteria)
- Major Vascular Complications
- Minor Vascular Complications
- Acute Kidney Injury (AKI)
- Major Adverse Cardiac and Cerebral Events (MACCE)
- Death



**SCAI**

Society for Cardiovascular  
Angiography & Interventions

# Study Design



# Clinical Outcomes

30 Day Clinical Outcomes	PS	PG	Unadjusted OR	p-value	Adjusted OR	p-value
<b>Major/Minor Vascular Complications</b>	86 (24%)	61 (15%)	0.57 (0.39 – 0.82)	<b>0.02</b>	0.54 (0.37 – 0.80)	<b>&lt;0.01</b>
Major Vascular Complications	41 (12%)	28 (7%)	0.58 (0.35 – 0.96)	0.03	0.62 (0.37 – 1.04)	0.07
<b>Minor Vascular Complications</b>	47 (13%)	33 (8%)	0.59 (0.37 – 0.95)	<b>0.03</b>	0.55 (0.34 – 0.90)	<b>0.02</b>
Major Bleeding (BARC ≥3b)	39 (11%)	33 (8%)	0.73 (0.45 – 1.19)	0.21	0.74 (0.45 – 1.22)	0.23
Any BARC Bleeding	167 (47%)	194 (49%)	1.07 (0.80 – 1.43)	0.49	1.10 (0.82 – 1.49)	0.52
<b>Acute Kidney Injury</b>	70 (25%)	57 (17%)	0.68 (0.46 – 1.00)	<b>0.05</b>	0.61 (0.40 – 0.90)	<b>0.01</b>
MACCE	28 (8%)	32 (8%)	1.02 (0.60 – 1.74)	0.93	1.09 (0.64 – 1.88)	0.74
Death	21 (6%)	16 (4%)	0.67 (0.34 – 1.30)	0.23	0.80 (0.41 – 1.59)	0.53

# Conclusions

- Access-site related **vascular complications occurred in 24%** of all patients following transfemoral TAVR
- ProGlide was associated with significantly **lower rates of 30-day major or minor vascular complications**
- ProGlide was associated with **lower risk of acute kidney injury**
- ProGlide may be associated with **shorter length of hospital stay and shorter procedural duration**



**SCAI**

Society for Cardiovascular  
Angiography & Interventions

Thank you for your attention

Questions and Comments to:

[David.Power@mountsinai.org](mailto:David.Power@mountsinai.org)

[George.Dangas@mountsinai.org](mailto:George.Dangas@mountsinai.org)

[Roxana.Mehran@mountsinai.org](mailto:Roxana.Mehran@mountsinai.org)



**SCAI**

Society for Cardiovascular  
Angiography & Interventions